Glide Pharma signs biologicals deal with major pharma company

28-Feb-2008

Glide Pharma has signed an agreement with a pharmaceutical company to evaluate its proprietary Glide SDI(tm) - Solid Dose Injector - technology for the delivery of a branded peptide product. This is Glide Pharma's third deal involving a biological product, with further agreements close to fruition.

The deal is described as a future-directed relationship, focusing initially on one of the pharma company's branded biologicals; the new partner has also taken an option to enter into a full development programme. Under the terms of the deal, Glide Pharma will develop and test a range of solid dosage formulations of the branded peptide in the unique Glide SDI. These formulations will then be supplied to the partner company for further evaluation.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances